Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1 By Ogkologos - July 1, 2025 681 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KOMET study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR FDA Approves First Comprehensive Pan-Tumour Liquid Biopsy Test for Patients with... September 3, 2020 CVS, Walgreens, Rite Aid Suspend Sales Of Zantac Following Cancer-Causing Concerns October 11, 2019 How to Strengthen Your Immune System: Part 2 September 18, 2020 How People With Cancer Can Benefit From Online Therapy October 22, 2020 Load more HOT NEWS News digest – naked mole-rats, junk food deals, ovarian cancer drug... It’s a fair COP: Why our chief clinician went to a... FDA Approves Pralsetinib for Non-Small Cell Lung Cancer with RET Gene... Selpercatinib Shows Durable Efficacy in RET-Altered Thyroid Cancer
